Secondary Adjuvant Long Term Study With Arimidex

Inclusion criteria

• Postmenopausal patients with histologically confirmed, local radically treated invasive or minimal-invasiv Mammacarcinom with or without previous chemotherapie and/or radiotherapie.
• No distant metastasis at randomization
• No relapse at randomization
• TNM- classification at time of diagnosis: T1-3, N0 and N+, M0
• Estrogen- and or progesterone positive before the beginningof primary endocrine therapy
• Endocrine therapy for 5 years (maximum deviation ±12 months)
• Therapy break (from the preliminary therapie) maximum 12 months.
• Informed Consent before the randomisation

Exclusion criteria

• Premenopausal patients or patients with non definable menopausal statusat time of randomisation
• Apparent secondary malignant tumor or status after secondary malignant tumor (Exceptions: simultaniously appearing bilateral breast carcinoma, estrogen- and or progesteronereceptor positive on both sides at the time of diagnosis; in situ carcinomaof the cervix and basal cell carcinoma of the skin)
• General contraindication respectively hypersensitivity to Anastrozol.
• In-situ carcinoma of any size with or without Mb. Paget of the Mamilla respectively T4 tumor at the time of first diagnosis.
• Receptor unknown or negative at time of diagnosis respectively at beginning of primary endocrine therapy
• Known liver- and/or kidneyinsufficiency
• Performance Index >2 according to WHO
• Regular intake of hormon supplement as well as Hormone Replacement Therapy (HRT) more than 6 months since primary surgery of the mamma carcinoma
• Serious accessory disease, that prevents the adjuvant therapy according to protocol and/or the regular follow-up care.
• Lacking compliance of the patient
• Legal incompetence and/or other circumstances, that prevent the patient from understanding the nature, meaning and consequences of the clinical trial
• Existing psychiatrical diseaseaccording to ICD (especially alcohol addiction) et the time of admission into the study